Earnings Insights

Route Mobile Q1 FY26 quarterly results analysis. - Route Mobile aims to continue industry-leading revenue growth despite global uncertainties. Market Cap ₹3,350, P/E 9.5. AI-powered earnings insights.

5 Aug 2026

Route Mobile Q4 FY25 quarterly results analysis. - The company targets a 15% CAGR revenue growth over the next three years, reflecting an industry-leading growth trajectory despite macro headwinds. Market Cap ₹3,350, P/E 9.5. AI-powered earnings insights.

5 Aug 2026

Happiest Minds Q4 FY26 quarterly results analysis. - Happiest Minds expects to maintain and potentially accelerate its 10%+ revenue growth guidance for FY'27, building on a 10.2% Y-o-Y growth in the first 9 months of FY'26. Market Cap ₹6,108, P/E 26.0. AI-powered earnings insights.

5 Aug 2026

Happiest Minds Q2 FY26 quarterly results analysis. - Expecting double-digit growth in constant currency for the full year, with Q2 and H2 anticipated to outperform Q1 (2.3% growth). Market Cap ₹6,108, P/E 26.0. AI-powered earnings insights.

5 Aug 2026

Happiest Minds Q4 FY25 quarterly results analysis. - Expect solid organic growth, especially from the Generative AI Business Services (GBS) and verticalization initiatives. Market Cap ₹6,108, P/E 26.0. AI-powered earnings insights.

5 Aug 2026

Borosil Q4 FY26 quarterly results analysis. - Borosil Limited is confident about future growth driven by market shifts towards glassware, healthier options, and stainless steel products. Market Cap ₹2,900, P/E 37.3. AI-powered earnings insights.

5 Aug 2026

Borosil Q2 FY26 quarterly results analysis. - Management targets a medium-term revenue CAGR of 15% to 20%, maintaining bullish outlook despite recent muted demand. Market Cap ₹2,900, P/E 37.3. AI-powered earnings insights.

5 Aug 2026

Borosil Q1 FY26 quarterly results analysis. - Borosil aims to return to a growth path next year with a year-on-year growth target of 15% to 20%. Market Cap ₹2,900, P/E 37.3. AI-powered earnings insights.

5 Aug 2026

Max Healthcare Q3 FY26 quarterly results analysis. - Network gross revenue grew 24% YoY to INR 5,266 crore in the recent quarter, indicating strong ongoing growth. Market Cap ₹105,897, P/E 71.4. AI-powered earnings insights.

5 Aug 2026

Max Healthcare Q2 FY26 quarterly results analysis. - Max Healthcare reported a strong 27% year-on-year revenue growth in Q1 FY '26, driven by successful hospital acquisitions and integrations. - Existing units showed a 16% revenue growth, with like-for-like ARPOB growth of 5% year-on-year. - Occupancy in base hospitals

5 Aug 2026

Max Healthcare Q1 FY26 quarterly results analysis. - Max Healthcare expects strong growth driven by recent acquisitions (Lucknow, Nagpur, Jaypee Noida) and new facilities (Dwarka, brownfield expansions). Market Cap ₹105,897, P/E 71.4. AI-powered earnings insights.

5 Aug 2026

Rossari Biotech Q4 FY26 quarterly results analysis. - Export growth expected to continue outperforming domestic growth, though at a moderated pace compared to the 26% YoY seen in 9M FY26. Market Cap ₹2,903, P/E 19.3. AI-powered earnings insights.

5 Aug 2026

Mindspace Busine Q2 FY26 quarterly results analysis. - Mindspace REIT delivered strong Q1 FY'26 results with 24.2% YoY NOI growth and 21.4% revenue growth. Market Cap ₹32,592, P/E 48.2. AI-powered earnings insights.

5 Aug 2026

Mindspace Busine Q4 FY25 quarterly results analysis. - The acquisition of Commerzone Raidurg, a top-class asset in prime CBD Madhapur, Hyderabad, is expected to add significant value and growth to Mindspace REIT's portfolio. - The acquisition adds Rs. Market Cap ₹32,592, P/E 48.2. AI-powered earnings insights.

5 Aug 2026

Rossari Biotech Q3 FY26 quarterly results analysis. - Revenue growth in Q2 FY26 was strong at 18% YoY, driven largely by volume increases across all verticals (HPPC, TSC, AHN). - Exports grew robustly by 36% YoY in Q2 and 27% in H1, now comprising nearly 28% of total revenue, with growth driven by new geographies like

5 Aug 2026

Rossari Biotech Q2 FY26 quarterly results analysis. - Rossari Biotech expects mid-double-digit revenue growth of around 14%-15% annually over the next 2 years. Market Cap ₹2,903, P/E 19.3. AI-powered earnings insights.

5 Aug 2026

Rossari Biotech Q1 FY26 quarterly results analysis. - Rossari Biotech targets mid-teens percentage growth in overall business revenue, with an annual growth rate around 15% (Page 4, 6). - Ethoxylation capacity expansion expected to be commissioned by Q2 FY26, supporting growth in key segments (Page 4). - HPPC (Home and

5 Aug 2026

Altius Telecom Q3 FY26 quarterly results analysis. - Revenue and EBITDA CAGR expected to be in the range of 4% to 7%, driven by both tower additions and tenancy growth. Market Cap ₹52,114, P/E 48.7. AI-powered earnings insights.

5 Aug 2026

Cohance Life Q4 FY26 quarterly results analysis. - Management remains committed to the USD 1 billion sales target by FY '30, though timing may shift slightly due to current challenges. Market Cap ₹16,418, P/E 152.5. AI-powered earnings insights.

5 Aug 2026

Prince Pipes Q2 FY26 quarterly results analysis. No information is provided regarding the same in the latest conference call. Market Cap ₹3,034, P/E 29.1. AI-powered earnings insights.

5 Aug 2026